Interim report July – September 2024
THIRD QUARTER (JULY - SEPTEMBER 2024)
- Order intake SEK 253.4 M (240.7)
- Net sales SEK 293.3 (252.9)
- Operating profit SEK 61.8 M (28,6)
- Profit after tax SEK 45.4 M (21,6)
- Earnings per share before/after dilution SEK 1.32 (0.63)
- Cash flow from operating activities SEK 60.5 M (124.4)
- Order backlog SEK 1,732.0 M (1,966.3) at the end of the period
NINE MONTHS (JANUARY – SEPTEMBER 2024)
- Order intake SEK 782.1 M (686.5)
- Net sales SEK 869.4 M (722.5)
- Operating profit SEK 186.9 M (70.5)
- Profit after tax SEK 143.5 M (50.0)
- Earnings per share before/after dilution SEK 4.19 (1.46)
- Cash flow from operating activities SEK 382.3 M (340.2)
SIGNIFICANT EVENTS DURING THE SECOND QUARTER
- Connect Proton Therapy Center in the USA has placed an order for RayStation
- Iridium Network first center in the world to use RayCare with TrueBeam to treat a patient
SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD
- GenesisCare in the UK has placed an order for RayStation
- RaySearch now has more than 100 RayStation customers in China
- Three centers in the French Unicancer network choose RayStation
- Nina Grönberg has been appointed as the new CFO and will take office in January 2025
- Institut Curie selects RayStation for proton planning
- The Board has decided to raise the target for the operating margin to at least 25 (20) percent by 2026
WEBCAST
CEO Johan Löf and Interim CFO Annika Blondeau Henriksson will present RaySearch’s interim report for July-September 2024 in a webcast to be held in English on Friday, November 8, 2024, at 10:00 a.m. CET.
Link to webcast: RaySearch Q3, 2024
The information contained in this interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on November 8, 2024, at 7:45 a.m. CET.
FOR MORE INFORMATION, PLEASE CONTACT:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
Annika Blondeau Henriksson, Interim CFO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
annika.henriksson@raysearchlabs.com
ABOUT RAYSEARCH
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.
RaySearch's software has been sold to over 1,000 clinics in 44 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com.
* Subject to regulatory clearance in some markets.
Tags: